SCHEDULE: Nantahala Capital Discloses 5.09% Stake in Abeona Therapeutics

Nantahala Capital Partners Limited Partnership has reported a passive beneficial ownership of 5.09% in Abeona Therapeutics Inc., totaling 2,618,462 common shares.

Summary

• Nantahala Capital Partners Limited Partnership reported beneficial ownership of 2,618,462 shares of Abeona Therapeutics Inc. common stock.
• This stake represents 5.09% of the total class outstanding.
• The ownership percentage is based on 51,278,539 shares outstanding, as reported by the issuer in its August 14, 2025 10-Q for June 30, 2025.
• The reported shares include 179,832 shares that Nantahala Capital Partners Limited Partnership may acquire within sixty days through the exercise of securities.
• Nantahala Capital Partners Limited Partnership holds shared voting and shared dispositive power over all 2,618,462 beneficially owned shares.
• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Abeona Therapeutics Inc.

Sentiment

Score: 6

Explanation: The filing indicates a new passive institutional investment in Abeona Therapeutics Inc. by Nantahala Capital Partners, which can be viewed as a positive signal of investor confidence. However, it does not contain operational or financial performance data to significantly alter sentiment.

Positives

• A significant institutional investor, Nantahala Capital Partners, has taken a 5.09% stake in Abeona Therapeutics Inc., which can be interpreted as a signal of confidence in the company's prospects.
• The investment includes 179,832 shares acquirable through the exercise of securities, indicating potential for increased commitment.

Negatives

• No specific negative points are disclosed in this Schedule 13G filing, as it primarily serves as a disclosure of passive ownership.

Risks

• The filing itself does not detail specific operational or financial risks for Abeona Therapeutics Inc. It is a disclosure of a passive investment position by an institutional investor.

Future Outlook

This filing does not provide forward-looking statements or guidance from the issuer or the reporting person regarding the issuer's future performance.

Industry Context

The disclosure of a new institutional stake in Abeona Therapeutics, a biotechnology company, is a common occurrence in the sector. Such investments can reflect investor interest in the company's pipeline, clinical trial progress, or market potential, particularly in the specialized areas of gene therapy and rare diseases.

Stakeholder Impact

• Shareholders: May view the new institutional investment as a positive indicator of market confidence, potentially influencing stock price.
• Company Management: The disclosure of a significant passive stake by an institutional investor may be noted, but it does not imply any immediate operational changes or influence on control.

Key Dates

Keywords

Abeona Therapeutics, Nantahala Capital, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investment, Biotechnology, Pharmaceutical, Gene Therapy, Rare Diseases